AMPK Cancer Research Results

AMPK, adenosine monophosphate-activated protein kinase: Click to Expand ⟱
Source:
Type:
AMPK: guardian of metabolism and mitochondrial homeostasis; Upon changes in the ATP-to-AMP ratio, AMPK is activated. (AMPK) is a key metabolic sensor that is pivotal for the maintenance of cellular energy homeostasis. It is well documented that AMPK possesses a suppressor role in the context of tumor development and progression by modulating the inflammatory and metabolic pathways.

-Activating AMPK can inhibit anabolic processes and the PI3K/Akt/mTOR pathway reducing glycolysis shifting toward Oxidative Phosphorlylation.


AMPK activators:
-metformin or AICAR
-Resveratrol: activate AMPK indirectly
-Berberine
-Quercetin: may stimulate AMPK
-EGCG: thought to activate AMPK
-Curcumin: may activate AMPK

-Ginsenosides: Some ginsenosides have been associated with AMPK activation -Beta-Lapachone: A natural naphthoquinone compound found in the bark of Tabebuia avellanedae (also known as lapacho or taheebo). It has been observed to activate AMPK in certain models.
-Alpha-Lipoic Acid (ALA): associated with AMPK activation
Stroke, Cerebral Ischemic Stroke: Click to Expand ⟱
Ischemic stroke is also called brain ischemia and cerebral ischemia. Ischemia is the medical term for "lack of blood supply."

Quick Reference

Mechanism Top Compounds
Blood flow / anti-thrombotic support Aspirin, Ginkgo biloba, Panax notoginseng, Salvia miltiorrhiza
Membrane repair / cholinergic support Citicoline, Alpha-GPC
Antioxidant / ROS control EGCG, Curcumin, Quercetin, Tocotrienols
Anti-inflammatory / NF-κB / cytokines Curcumin, Luteolin, Baicalin
Mitochondrial protection Resveratrol, Citicoline
Blood flow / anti-thrombotic support Ginkgo biloba, Panax notoginseng, Salvia miltiorrhiza
BBB protection Rosmarinic acid, Astragaloside IV

Stroke/Product Table - Dose + Practical Therapeutic Index

Compound Class Primary Mechanisms Key Stroke Effects Evidence Level Phase Utility Human Dose Range Approx. HED mg/kg/day Practical Therapeutic Index
Aspirin NSAID / anti-platelet COX-1 inhibition; ↓ thromboxane A2; ↓ platelet aggregation Reduces recurrent ischemic stroke risk Strong clinical; standard of care Acute + prevention 81–325 mg/day ~1.2–4.6 mg/kg/day for 70 kg adult High, but bleeding-risk limited
Citicoline / CDP-choline Choline donor Membrane repair; ↑ phosphatidylcholine; ↓ free fatty acid release May support neurological and cognitive recovery Clinical; mixed acute results, better recovery/cognition signal Recovery 500–2000 mg/day ~7–29 mg/kg/day for 70 kg adult Moderate–High
Alpha-GPC Choline donor ↑ acetylcholine; phospholipid support May support post-stroke cognition Clinical; moderate support Recovery 300–1200 mg/day ~4–17 mg/kg/day for 70 kg adult Moderate; TMAO concern
Ginkgo biloba Herbal extract Cerebral blood flow; antioxidant; anti-platelet May support perfusion and cognition Clinical + preclinical Recovery 120–240 mg/day standardized extract ~1.7–3.4 mg/kg/day Moderate; bleeding interaction caution
Panax notoginseng / PNS Saponins Anti-thrombotic; perfusion; anti-inflammatory Improved blood flow/recovery measures in some studies Clinical mainly China + preclinical Acute + recovery Variable extract-dependent Study-specific; often preclinical HED needed Moderate; bleeding interaction caution
Salvia miltiorrhiza / Danshen Herbal extract Microcirculation; vascular protection; anti-platelet May support vascular recovery Clinical mainly China + preclinical Acute + recovery Variable extract/root equivalent Study-specific Moderate; bleeding interaction caution
Baicalin Flavonoid Anti-inflammatory; anti-apoptotic; antioxidant Neuroprotection in ischemic injury models Preclinical + limited clinical Acute No established stroke dose Preclinical HED only Moderate–Low
Curcumin Polyphenol ↓ NF-κB; ↓ cytokines; antioxidant Reduced infarct size/inflammation in models Strong preclinical Acute + recovery 500–2000 mg/day bioavailable form ~7–29 mg/kg/day Moderate; bioavailability limited
Resveratrol Polyphenol SIRT1; mitochondrial protection; anti-apoptotic Reduced apoptosis/infarct injury in models Strong preclinical Acute + recovery 100–500 mg/day ~1.4–7.1 mg/kg/day Moderate; bioavailability limited
EGCG Catechin ROS scavenging; vascular protection Reduced neuronal injury in models Strong preclinical Acute 200–400 mg/day EGCG ~2.9–5.7 mg/kg/day Moderate; liver-dose caution
Quercetin Flavonoid Antioxidant; anti-inflammatory; anti-edema Reduced edema/infarct size in models Strong preclinical Acute 500–1000 mg/day ~7–14 mg/kg/day Moderate
Melatonin Indoleamine Mitochondrial antioxidant; anti-inflammatory Reduced ischemia-reperfusion injury in models Preclinical + limited clinical interest Acute + recovery 3–10 mg/day ~0.04–0.14 mg/kg/day Moderate–High
Tocotrienols Vitamin E subtype Lipid antioxidant; membrane protection Neuroprotection in ischemic models Preclinical + limited clinical Acute 100–300 mg/day ~1.4–4.3 mg/kg/day Moderate
Luteolin Flavonoid NF-κB / Nrf2 / PI3K-Akt modulation Reduced inflammation/neuroprotection in models Strong preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Ferulic acid Phenolic acid Antioxidant; vasodilation; vascular protection Improved blood flow/reduced injury in models Preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Rosmarinic acid Phenolic acid BBB protection; antioxidant; anti-inflammatory Reduced BBB disruption in models Preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Berberine Alkaloid AMPK activation; metabolic/vascular protection Neuroprotection in ischemia models Preclinical Prevention + recovery 500–1500 mg/day ~7–21 mg/kg/day Moderate; interaction caution
Huperzine A Alkaloid AChE inhibition; cholinergic support May support cognitive recovery Preclinical + cognitive clinical context Recovery 100–200 µg/day ~0.001–0.003 mg/kg/day Low–Moderate; narrow cholinergic tolerance
Honokiol Lignan Mitochondrial protection; anti-inflammatory Reduced ischemic neuronal injury in models Preclinical Acute + recovery No established stroke dose Preclinical HED only Low
HED: Human Equilvalent Dose
Scientific Papers found: Click to Expand⟱
2626- Ba,    Molecular targets and therapeutic potential of baicalein: a review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
AntiCan↓, *neuroP↑, *cardioP↑, *hepatoP↑, *RenoP↑, TumCCA↑, CDK4↓, cycD1/CCND1↓, cycE/CCNE↑, BAX↑, Bcl-2↓, VEGF↓, Hif1a↓, cMyc↓, NF-kB↓, ROS↑, BNIP3↑, *neuroP↑, *cognitive↑, *NO↓, *iNOS↓, *COX2↓, *PGE2↓, *NRF2↑, *p‑AMPK↑, *Ferroptosis↓, *lipid-P↓, *ALAT↓, *AST↓, *Fas↓, *BAX↓, *Apoptosis↓,
5552- BBM,    Effects of berbamine against myocardial ischemia/reperfusion injury: Activation of the 5' adenosine monophosphate‐activated protein kinase/nuclear factor erythroid 2‐related factor pathway and changes in the mitochondrial state
- in-vivo, Stroke, NA
*eff↑, *ROS↓, *mtDam↓, *AMPK↑, *NRF2↑, *NADPH↑, *HO-1↑, *cardioP↑,
6002- CGA,    Chlorogenic Acid: A Systematic Review on the Biological Functions, Mechanistic Actions, and Therapeutic Potentials
- Review, Var, NA - Review, Diabetic, NA - Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*neuroP↑, *Inflam↓, *antiOx↑, *cardioP↑, *NRF2↑, *AMPK↑, *SOD↑, *Catalase↑, *GSH↑, *GPx↑, *ROS↓, *TNF-α↓, *IL6↓, *NF-kB↓, *COX2↓, *glucose↓, *TRPC1↓, *Ca+2↓, *HO-1↑, *NF-kB↓, *PPARα↝, *Hif1a↓, *JNK↓, *BP↓, *AntiDiabetic↑, *hepatoP↑, *TLR4↓, *NRF2↑, *Casp↓, *neuroP↑, *Aβ↓, *LDH↓, *MDA↓, *memory↑, *AChE↓, *eff↑, EMT↝, N-cadherin↓, E-cadherin↑, TumCCA↑, ROS↑, p‑P53↑, HO-1↑, NRF2↑, ChemoSen↑, mtDam↑, Casp3↑, Casp9↑, PARP↑, Bax:Bcl2↑, TumCG↓, cycD1/CCND1↓, cMyc↓, CDK2↓, mitResp↓, Glycolysis↓, Hif1a↓, PCNA↓, p‑GSK‐3β↓, VEGF↓, PI3K↓, Akt↓, mTOR↓, OS↑,
2566- RES,    A comprehensive review on the neuroprotective potential of resveratrol in ischemic stroke
- Review, Stroke, NA
*neuroP↑, *NRF2↑, *SIRT1↑, *PGC-1α↑, *FOXO↑, *HO-1↑, *NQO1↑, *ROS↓, *BP↓, *BioAv↓, *Half-Life↝, *AMPK↑, *GSK‐3β↓, *eff↑, *AntiAg↑, *BBB↓, *Inflam↓, *MPO↓, *TLR4↓, *NF-kB↓, *p65↓, *MMP9↓, *TNF-α↓, *IL1β↓, *PPARγ↑, *MMP↑, *ATP↑, *Cyt‑c∅, *mt-lipid-P↓, *H2O2↓, *HSP70/HSPA5↝, *Mets↝, *eff↑, *eff↑, *motorD↑, *MDA↓, *NADH:NAD↑, eff↑, eff↑,
4284- RES,    Resveratrol induces dephosphorylation of Tau by interfering with the MID1-PP2A complex
- in-vitro, AD, HEK293 - NA, Stroke, NA - in-vivo, AD, NA
*p‑tau↓, *PP2A↑, *neuroP↑, *antiOx↑, COX2↓, *AntiAg↑, *SIRT1↑, *AMPK↑, *Acetyl-CoA↓, *FAO↑, *ADAM10↑, *BACE↓, *Aβ↓, *memory↑, *Inflam↓, *ROS↓,
3319- SIL,    Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*neuroP↑, *ROS↓, *Inflam↓, *Apoptosis↓, *BBB?, *tau↓, *NF-kB↓, *IL1β↓, *TNF-α↓, *IL4↓, *MAPK↓, *memory↑, *cognitive↑, *Aβ↓, *ROS↓, *lipid-P↓, *GSH↑, *MDA↓, *SOD↑, *Catalase↑, *AChE↓, *BChE↓, *p‑ERK↓, *p‑JNK↓, *p‑p38↓, *GutMicro↑, *COX2↓, *iNOS↓, *TLR4↓, *neuroP↑, *Strength↑, *AMPK↑, *MMP↑, *necrosis↓, *NRF2↑, *HO-1↑,
4869- Uro,    Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges
- Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*MitoP↑, *Inflam↓, *antiOx↑, *Risk↓, *Aβ↓, *p‑tau↓, *p62↓, *PARK2↑, *MMP↑, *ROS↓, *Strength↑, *CRP↓, *IL1β↓, *IL6↓, *TNF-α↓, *AMPK↑, *NF-kB↓, *MAPK↓, *p62↑, *NRF2↑, *SOD↑, *Catalase↑, *HO-1↑, *Ferroptosis↓, *lipid-P↓, *Cartilage↑, *PI3K↓, *Akt↓, *mTOR↓, *Apoptosis↓, *neuroP↑, *Bcl-2↓, *BAX↑, *Casp3↑, *ATP↑, *eff↑, *motorD↑, *NLRP3↓, *radioP↑, *BBB↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

HO-1↑, 1,   NRF2↑, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

mitResp↓, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 2,   Glycolysis↓, 1,  

Cell Death ⓘ

Akt↓, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp9↑, 1,  

Autophagy & Lysosomes ⓘ

BNIP3↑, 1,  

DNA Damage & Repair ⓘ

p‑P53↑, 1,   PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

EMT↝, 1,   p‑GSK‐3β↓, 1,   mTOR↓, 1,   PI3K↓, 1,   TumCG↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   N-cadherin↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 2,   VEGF↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 2,  

Functional Outcomes ⓘ

AntiCan↓, 1,   OS↑, 1,  
Total Targets: 37

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↑, 3,   Ferroptosis↓, 2,   GPx↑, 1,   GSH↑, 2,   H2O2↓, 1,   HO-1↑, 5,   lipid-P↓, 3,   mt-lipid-P↓, 1,   MDA↓, 3,   Mets↝, 1,   MPO↓, 1,   NQO1↑, 1,   NRF2↑, 7,   PARK2↑, 1,   ROS↓, 7,   SOD↑, 3,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 2,   MMP↑, 3,   mtDam↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

Acetyl-CoA↓, 1,   ALAT↓, 1,   AMPK↑, 6,   p‑AMPK↑, 1,   FAO↑, 1,   glucose↓, 1,   LDH↓, 1,   NADH:NAD↑, 1,   NADPH↑, 1,   PPARα↝, 1,   PPARγ↑, 1,   SIRT1↑, 2,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↓, 3,   BAX↓, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp↓, 1,   Casp3↑, 1,   Cyt‑c∅, 1,   Fas↓, 1,   Ferroptosis↓, 2,   iNOS↓, 2,   JNK↓, 1,   p‑JNK↓, 1,   MAPK↓, 2,   necrosis↓, 1,   p‑p38↓, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↝, 1,  

Autophagy & Lysosomes ⓘ

MitoP↑, 1,   p62↓, 1,   p62↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1,   FOXO↑, 1,   GSK‐3β↓, 1,   mTOR↓, 1,   PI3K↓, 1,  

Migration ⓘ

AntiAg↑, 2,   Ca+2↓, 1,   Cartilage↑, 1,   MMP9↓, 1,   TRPC1↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,   NO↓, 1,  

Barriers & Transport ⓘ

BBB?, 1,   BBB↓, 1,   BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   CRP↓, 1,   IL1β↓, 3,   IL4↓, 1,   IL6↓, 2,   Inflam↓, 5,   NF-kB↓, 5,   p65↓, 1,   PGE2↓, 1,   TLR4↓, 3,   TNF-α↓, 4,  

Synaptic & Neurotransmission ⓘ

AChE↓, 2,   ADAM10↑, 1,   BChE↓, 1,   tau↓, 1,   p‑tau↓, 2,  

Protein Aggregation ⓘ

Aβ↓, 4,   BACE↓, 1,   NLRP3↓, 1,   PP2A↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   eff↑, 6,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   BP↓, 2,   CRP↓, 1,   GutMicro↑, 1,   IL6↓, 2,   LDH↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 3,   cognitive↑, 2,   hepatoP↑, 2,   memory↑, 3,   motorD↑, 2,   neuroP↑, 9,   radioP↑, 1,   RenoP↑, 1,   Risk↓, 1,   Strength↑, 2,  
Total Targets: 109

Scientific Paper Hit Count for: AMPK, adenosine monophosphate-activated protein kinase
2 Resveratrol
1 Baicalein
1 Berbamine
1 Chlorogenic acid
1 Silymarin (Milk Thistle) silibinin
1 Urolithin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:36  Cells:%  prod#:%  Target#:9  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page